Departments of Oncology and Community Health Sciences (Brenner), Cumming School of Medicine, University of Calgary, Calgary, Alta.; Surveillance, Canadian Cancer Society (Gillis), Vancouver, BC; Centre for Surveillance and Applied Research (Demers), Public Health Agency of Canada; Centre for Population Health Data (Ellison, Billette, Zhang, Liu), Statistics Canada, Ottawa, Ont.; Population Oncology, BC Cancer (Woods), Vancouver, BC; Department of Surgery (Finley), McMaster University and St. Joseph's Health Care Centre, Hamilton, Ont.; System Performance & Analytics (Fitzgerald), Canadian Partnership Against Cancer, Toronto, Ont.; Nova Scotia Health Cancer Care Program (Saint-Jacques), Halifax, NS; Cancer Advanced Analytics (Shack), Cancer Care Alberta, Calgary, Alta; Department of Community Health Sciences (Turner), Max Rady College of Medicine, University of Manitoba; Paul Albrechtsen Research Institute (Turner), CancerCare Manitoba, Winnipeg, Man.
CMAJ. 2024 May 12;196(18):E615-E623. doi: 10.1503/cmaj.240095.
Cancer surveillance data are essential to help understand where gaps exist and progress is being made in cancer control. We sought to summarize the expected impact of cancer in Canada in 2024, with projections of new cancer cases and deaths from cancer by sex and province or territory for all ages combined.
We obtained data on new cancer cases (i.e., incidence, 1984-2019) and deaths from cancer (i.e., mortality, 1984-2020) from the Canadian Cancer Registry and Canadian Vital Statistics Death Database, respectively. We projected cancer incidence and mortality counts and rates to 2024 for 23 types of cancer, overall, by sex, and by province or territory. We calculated age-standardized rates using data from the 2011 Canadian standard population.
In 2024, the number of new cancer cases and deaths from cancer are expected to reach 247 100 and 88 100, respectively. The age-standardized incidence rate (ASIR) and mortality rate (ASMR) are projected to decrease slightly from previous years for both males and females, with higher rates among males (ASIR 562.2 per 100 000 and ASMR 209.6 per 100 000 among males; ASIR 495.9 per 100 000 and ASMR 152.8 per 100 000 among females). The ASIRs and ASMRs of several common cancers are projected to continue to decrease (i.e., lung, colorectal, and prostate cancer), while those of several others are projected to increase (i.e., liver and intrahepatic bile duct cancer, kidney cancer, melanoma, and non-Hodgkin lymphoma).
Although the overall incidence of cancer and associated mortality are declining, new cases and deaths in Canada are expected to increase in 2024, largely because of the growing and aging population. Efforts in prevention, screening, and treatment have reduced the impact of some cancers, but these short-term projections highlight the potential effect of cancer on people and health care systems in Canada.
癌症监测数据对于了解癌症控制方面的差距和进展至关重要。我们旨在总结 2024 年加拿大癌症的预期影响,预测所有年龄段按性别和省/地区划分的新癌症病例和癌症死亡人数。
我们从加拿大癌症登记处和加拿大生命统计死亡数据库分别获取了新癌症病例(即发病率,1984-2019 年)和癌症死亡人数(即死亡率,1984-2020 年)的数据。我们预测了 23 种癌症的癌症发病率和死亡率计数和率,到 2024 年,按性别和省/地区划分。我们使用 2011 年加拿大标准人口数据计算了年龄标准化率。
2024 年,新癌症病例和癌症死亡人数预计分别达到 247100 例和 88100 例。预计男性和女性的年龄标准化发病率(ASIR)和死亡率(ASMR)将略低于前几年,男性的发病率和死亡率较高(男性的 ASIR 为每 100000 人 562.2 例,ASMR 为每 100000 人 209.6 例;女性的 ASIR 为每 100000 人 495.9 例,ASMR 为每 100000 人 152.8 例)。预计几种常见癌症的 ASIR 和 ASMR 将继续下降(即肺癌、结直肠癌和前列腺癌),而其他几种癌症的 ASIR 和 ASMR 将上升(即肝癌和肝内胆管癌、肾癌、黑色素瘤和非霍奇金淋巴瘤)。
尽管癌症的总体发病率和相关死亡率正在下降,但加拿大预计在 2024 年新病例和死亡人数将增加,这主要是由于人口的增长和老龄化。预防、筛查和治疗方面的努力降低了一些癌症的影响,但这些短期预测突出了癌症对加拿大人民和医疗保健系统的潜在影响。